Chronic treatment with rapamycin/sirolimus, a macrolide with anti-tumor and immunosuppressive activity on the mTOR pathway, was able to block LPS-inducted absence seizures, further suggesting an anti-epileptogenic inflammatory-like protective action [21]. The gene discussed is MTOR; the disease is Generalized non-motor (absence) seizure.